trending Market Intelligence /marketintelligence/en/news-insights/trending/BjIEwgJVkQnu9-gWgWocWQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Rhythm Pharmaceuticals prices $150M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Rhythm Pharmaceuticals prices $150M common stock offering

Rhythm Pharmaceuticals Inc. priced its public offering of 8,108,108 common shares at $18.50 apiece.

The company also granted underwriters a 30-day option to buy up to an additional 1,216,216 common shares at the same price.

The price corresponds to gross proceeds of about $150 million.

The offering is expected to close on Oct. 18, subject to customary conditions.

Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC and Cowen and Co. LLC are acting as joint book-running managers for the offering, while Needham & Co. LLC is lead manager.

Boston-based Rhythm Pharmaceuticals develops therapies for rare genetic disorders that result in life-threatening metabolic disorders. In August, its experimental drug setmelanotide was shown to reduce body weight and insatiable hunger, meeting the main goals of two late-stage trials.